Mefloquine anxiety, depression, unusual behavior, and suicidal ideations, among others. Neurologic effects include dizziness, loss of balance, and tinnitus. The label warns that mild symptoms may presage more serious ones, and that the drug should be discontinued at the first sign of symptoms. Mefloquine should not be used in people with a history of psychiatric problems. Central nervous system events requiring hospitalization occur in about one in 10,000 people taking mefloquine for malaria prevention, with milder events (e.g., dizziness, headache, insomnia, and vivid dreams) in up to 25%. When some measure of subjective severity is applied to the rating of adverse
International Association for the Treatment of Sexual Offenders the context of their family, school, and other social systems in order to fully understand and decide the treatment and care for the juvenile. Another important element to keep in mind when choosing a treatment is to base it on a developmental perspective, which means it is sensitive to developmental change. This is necessary because during adolescence the brain is not fully developmental and is subjected to change. During assessment and treatment focus not only on the risks of the youths but also their strengths. Keep in mind that sexual interests of youth do change over adolescence and sexual orientation